Edge Pharma Comprehensive Company Profile
Key Indicators
- Authorised Capital ₹ 100.00 Cr
as on 20-06-2024
- Paid Up Capital ₹ 43.10 Cr
as on 20-06-2024
- Company Age 34 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -22.03%
(FY 2021)
- Profit -299.07%
(FY 2021)
- Ebitda -1329.47%
(FY 2021)
- Net Worth -1434.16%
(FY 2021)
- Total Assets -2.13%
(FY 2021)
About Edge Pharma
The Corporate was formerly known as Faldrup Investments And Traders Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 100.00 Cr and a paid-up capital of Rs 43.10 Cr, as per Ministry of Corporate Affairs (MCA) records.
Jayshree Chandurkar, Manish Shah, and Sameer Chandurkar serve as directors at the Company.
- CIN/LLPIN
U67120MH1989PTC053742
- Company No.
053742
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Oct 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Edge Pharma Private Limited offer?
Edge Pharma Private Limited offers a wide range of products and services, including .
Who are the key members and board of directors at Edge Pharma?
Board Members(3)
Financial Performance and Corporate Structure Insights of Edge Pharma.
Edge Pharma Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 22.03% decrease. The company also saw a substantial fall in profitability, with a 299.07% decrease in profit. The company's net worth observed a substantial decline by a decrease of 1434.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Edge Pharma?
In 2021, Edge Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Brickstreet Technologies Llp
Active
2 years 11 months Jayshree Chandurkar and Sameer Chandurkar are mutual person
Great Heights Trade Lines Private Limited
Active 30 years 7 months Jayshree Chandurkar and Sameer Chandurkar are mutual person
Chandurkar Investments Pvt Ltd
Active 43 years 5 months Jayshree Chandurkar and Sameer Chandurkar are mutual person
Monetize Financial Services P Ltd
Active 34 years 10 months Jayshree Chandurkar and Sameer Chandurkar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Edge Pharma?
Edge Pharma has a workforce of 33 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Mar 26, 2018, Edge Pharma has raised a total of ₹ 10.52 Cr, with the most recent deal valued at ₹ 3 Cr. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
